What new Dupilumab data suggest about long-term immune control in allergic disease at Regeneron Pharmaceuticals
Ryerson Holding (NYSE: RYI) finalises Olympic Steel acquisition as North American metals consolidation accelerates
Vikran Engineering (NSE: VIKRAN) Q3 FY26 results show solar-led order book surge as margins reset during execution ramp-up
Ducon Infratechnologies (NSE: DUCON) Q3 FY26 results signal margin pressure even as carbon capture and AI bets move closer to execution
Read More 5 minute read Pharma Industry News What new Dupilumab data suggest about long-term immune control in allergic disease at Regeneron Pharmaceuticals New Dupilumab analyses highlight immune modulation claims. Read how Regeneron Pharmaceuticals is testing durability, reimbursement logic, and long-term strategy. bySoujanya RaviFebruary 14, 2026